Pfizer Inc. $PFE Shares Sold by State Street Corp

by · The Cerbat Gem

State Street Corp reduced its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 0.2% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 296,301,310 shares of the biopharmaceutical company’s stock after selling 669,218 shares during the period. State Street Corp owned about 0.05% of Pfizer worth $7,182,344,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the first quarter valued at about $27,000. Curio Wealth LLC boosted its position in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer in the second quarter valued at approximately $29,000. Finally, Howard Hughes Medical Institute purchased a new stake in Pfizer in the second quarter valued at approximately $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.39.

Check Out Our Latest Research Report on PFE

Pfizer Stock Performance

Shares of PFE opened at $25.78 on Tuesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The stock has a market capitalization of $146.55 billion, a PE ratio of 14.99 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a 50-day simple moving average of $25.21 and a 200-day simple moving average of $24.71.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend was Friday, November 7th. Pfizer’s dividend payout ratio is 100.00%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).